XML 27 R16.htm IDEA: XBRL DOCUMENT
v3.19.2

Development and License Agreements | 6 Months Ended
--- | ---
Jun. 30, 2019
Development And License Agreements [Abstract] |
Development and License Agreements | Note 10. Development and License Agreements Agreements with Fresenius Fresenius Kabi AG (“Fresenius”) manufactures and supplies the platelet and plasma systems to the Company under a supply agreement (the “Supply Agreement”). Fresenius is obligated to sell, and the Company is obligated to purchase, finished disposable kits for the Company’s platelet and plasma systems and the Company’s red blood cell system product candidate (the “RBC Sets”). The Supply Agreement permits the Company to purchase platelet and plasma systems and RBC Sets from third parties to the extent necessary to maintain supply qualifications with such third parties or where local or regional manufacturing is needed to obtain product registrations or sales. Pricing terms per unit are initially fixed and decline at specified annual production levels, and are subject to certain adjustments after the initial pricing term. Under the Supply Agreement, the Company maintains the amounts due from the components sold to Fresenius as a current asset on its accompanying condensed consolidated balance sheets until such time as the Company purchases finished disposable kits using those components. The Supply Agreement also requires the Company to make certain payments totaling €8.6 million (“Manufacturing and Development Payments”) to Fresenius. In 2016, the Company paid €3.1 million to Fresenius. In August 2018, the Company entered into an amendment to the Supply Agreement accelerating the payment for the remaining €5.5 million to August 2019. Because these payments represent unconditional payment obligations, the Company recognized its liability for these payments at their net present value at discount rate of 9.72% based on the Company’s effective borrowing rate at that time. The Manufacturing and Development Payments liability is accreted through interest expense based on the estimated timing of its ultimate settlement. As of June 30, 2019 and December 31, 2018, the Company accrued $6.2 million (€5.5 million) and $5.9 million (€5.2 million), respectively, related to the Manufacturing and Development Payments, which were included in “Manufacturing and development obligations –current” in the Company’s condensed consolidated balance sheets. The Supply Agreement also requires the Company to make payments to support certain projects Fresenius has and will perform on behalf of the Company related to certain R&D activities and manufacturing efficiency activities for which certain assets have been established in the Company’s condensed consolidated balance sheets. The manufacturing efficiency asset is expensed on a straight-line basis over the life of the Supply Agreement. The prepaid asset related to amounts paid up front for the R&D activities to be conducted by Fresenius on behalf of the Company is expensed over the period which such activities occur. The following table summarizes the amounts of prepaid R&D asset and manufacturing efficiency asset at June 30, 2019 and December 31, 2018 (in thousands).
|  | June 30, 2019 |  |  | December 31, 2018 |
Prepaid R&D asset – current (1) |  | $ | 46 |  |  | $ | 47 |
Prepaid R&D asset – non-current (2) |  |  | 2,152 |  |  |  | 2,156 |
Manufacturing efficiency asset (2) |  |  | 1,472 |  |  |  | 1,594 |
(1) | Included in “Other current assets” in the Company's condensed consolidated balance sheets.
(2) | Included in “Other assets” in the Company's condensed consolidated balance sheets.
The initial term of the Supply Agreement extends through July 1, 2025 (the “Initial Term”) and is automatically renewed thereafter for additional two year terms (each, a “Renewal Term”), subject to termination by either party upon (i) two years written notice prior to the expiration of the Initial Term or (ii) one year written notice prior to the expiration of any Renewal Term. Under the Supply Agreement, the Company has the right, but not the obligation, to purchase certain assets and assume certain liabilities from Fresenius. The Company made payments to Fresenius of $5.6 million and $4.8 million relating to the manufacturing of the Company’s products during the three months ended June 30, 2019 and 2018, respectively, and $13.4 million and $10.2 million during the six months ended June 30, 2019 and 2018, respectively. The following table summarizes the amounts of the Company’s payables to and receivables from Fresenius at June 30, 2019 and December 31, 2018 (in thousands).
|  | June 30, 2019 |  |  | December 31, 2018 |
Payables to Fresenius (1) |  | $ | 9,974 |  |  | $ | 7,812 |
Receivables from Fresenius (2) |  |  | 1,636 |  |  |  | 1,777 |
(1) | Included in “Accounts Payable” and “Accrued Liabilities” in the Company's condensed consolidated balance sheets.
(2) | Included in “Other current assets” in the Company's condensed consolidated balance sheets.
Agreement with BARDA In June 2016, the Company entered into an agreement with BARDA to support the Company’s development and implementation of pathogen reduction technology for platelet, plasma, and red blood cells. The five-year agreement with BARDA and its subsequent modifications include a base period (the “Base Period”) and options (each, an “Option Period”) with committed funding of up to $103.2 million for clinical development of the INTERCEPT Blood System for red blood cells (the “red blood cell system”), and the potential for the exercise by BARDA of subsequent Option Periods that, if exercised by BARDA and completed, would bring the total funding opportunity to $201.2 million over the five-year contract period. If exercised by BARDA, subsequent Option Periods would fund activities related to broader implementation of the platelet and plasma system or the red blood cell system in areas of Zika virus risk, clinical and regulatory development programs in support of the potential licensure of the red blood cell system in the U.S., and development, manufacturing and scale-up activities for the red blood cell system. The Company is responsible for co-investment of $5.0 million and would be responsible for an additional $9.6 million, if certain Option Periods are exercised. BARDA will make periodic assessments of the Company’s progress and the continuation of the agreement is based on the Company’s success in completing the required tasks under the Base Period and each exercised Option Period. BARDA has rights under certain contract clauses to terminate the agreement, including the ability to terminate the agreement for convenience at any time. As of June 30, 2019 and December 31, 2018, $4.2 million and $2.3 million, respectively, of billed and unbilled amounts were included in accounts receivable on the Company’s condensed consolidated balance sheets related to BARDA.

X
- Definition Development and license agreements. + References No definition available. + Details
Name: | cers_DevelopmentAndLicenseAgreementsAbstract
Namespace Prefix: | cers_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Development and license agreements. + References No definition available. + Details
Name: | cers_DevelopmentAndLicenseAgreementsTextBlock
Namespace Prefix: | cers_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration